Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Chronic Lymphocytic Leukemia

Phase 1

Completed

Conditions: Leukemia

Interventions: Biological: Filgrastim (G-CSF)
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Procedure: Peripheral Blood Stem Cell Transplantation

First Posted Date: 2004-06-16

Last Posted Date: 2012-07-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 13

Registration Number: NCT00002838

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Chemotherapy in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: cyclophosphamide
Drug: fludarabine phosphate

First Posted Date: 2004-06-16

Last Posted Date: 2016-12-07

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 34

Registration Number: NCT00003829

Locations: 🇺🇸
CCOP - Scottsdale Oncology Program, Scottsdale, Arizona, United States
🇺🇸
Quain & Ramstad Clinic, P.C., Bismarck, North Dakota, United States
🇺🇸
CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States

and more 14 locations

Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

Phase 2

Completed

Conditions: Melanoma (Skin)

Interventions: Biological: aldesleukin
Biological: sargramostim
Drug: cyclophosphamide
Drug: fludarabine phosphate

First Posted Date: 2004-06-11

Last Posted Date: 2013-04-10

Lead Sponsor: Dartmouth-Hitchcock Medical Center

Target Recruit Count: 20

Registration Number: NCT00085423

Locations: 🇺🇸
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States

Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma

Phase 1

Completed

Conditions: Melanoma (Skin)

First Posted Date: 2004-06-11

Last Posted Date: 2012-06-22

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Target Recruit Count: 61

Registration Number: NCT00085462

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
🇺🇸
NCI - Surgery Branch, Bethesda, Maryland, United States

Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

Phase 1

Withdrawn

Conditions: Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms

Interventions: Biological: alemtuzumab
Drug: cyclosporine
Drug: fludarabine phosphate
Drug: melphalan
Drug: mycophenolate mofetil
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy

First Posted Date: 2004-06-11

Last Posted Date: 2019-11-27

Lead Sponsor: Alliance for Clinical Trials in Oncology

Registration Number: NCT00085449

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Siteman Cancer Center at Barnes-Jewish Hospital, Saint Louis, Missouri, United States

and more 21 locations

Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases

Phase 2

Conditions: Lymphoma
Fanconi Anemia
Myelodysplastic Syndromes
Sarcoma
Leukemia
Childhood Langerhans Cell Histiocytosis
Neuroblastoma
Unspecified Childhood Solid Tumor, Protocol Specific

Interventions: Biological: anti-thymocyte globulin
Drug: cyclophosphamide
Drug: busulfan
Radiation: radiation therapy
Drug: melphalan
Drug: fludarabine phosphate
Drug: methylprednisolone

First Posted Date: 2004-06-11

Last Posted Date: 2014-01-10

Lead Sponsor: Milton S. Hershey Medical Center

Target Recruit Count: 25

Registration Number: NCT00084695

Locations: 🇺🇸
Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States

Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer

Phase 1

Completed

Conditions: Cutaneous B-cell Non-Hodgkin Lymphoma
Juvenile Myelomonocytic Leukemia
Acute Undifferentiated Leukemia
Adult Nasal Type Extranodal NK/T-cell Lymphoma
Childhood Diffuse Large Cell Lymphoma
Childhood Nasal Type Extranodal NK/T-cell Lymphoma
Childhood Grade III Lymphomatoid Granulomatosis
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
Peripheral T-cell Lymphoma
Previously Treated Myelodysplastic Syndromes

Interventions: Radiation: total-body irradiation
Drug: fludarabine phosphate
Drug: cyclosporine
Drug: mycophenolate mofetil
Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Biological: donor lymphocytes
Procedure: peripheral blood stem cell transplantation
Other: laboratory biomarker analysis

First Posted Date: 2004-06-09

Last Posted Date: 2020-01-21

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 21

Registration Number: NCT00006251

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
🇮🇹
University of Torino, Torino, Italy

Radiation Therapy Plus Fludarabine in Treating Patients With Locally Advanced Cancer of the Mouth, Pharynx, or Larynx

Phase 1

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Fludarabine Phosphate
Radiation: Radiation Therapy (RT)

First Posted Date: 2004-05-03

Last Posted Date: 2018-10-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 16

Registration Number: NCT00004246

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Allogeneic Transplantation Using Mini-Conditioning for Treatment of Stage IV Breast Cancer

Phase 2

Withdrawn

Conditions: Breast Cancer

First Posted Date: 2004-04-29

Last Posted Date: 2010-06-10

Lead Sponsor: Case Comprehensive Cancer Center

Registration Number: NCT00006261

Locations: 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia

Phase 2

Withdrawn

Conditions: Graft Versus Host Disease
Leukemia

First Posted Date: 2004-04-28

Last Posted Date: 2020-07-31

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00004878

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy